U.S. markets closed

Genetron Holdings Limited (GTH)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
22.77+2.25 (+10.96%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Williams %R

Williams %R

Previous Close20.52
Open20.50
Bid22.89 x 1100
Ask23.25 x 1300
Day's Range20.31 - 23.38
52 Week Range9.03 - 31.54
Volume687,527
Avg. Volume410,183
Market Cap2.012B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateMar 25, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est26.22
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Genetron Health to Present at the SVB Leerink CybeRx Series: Liquid Biopsy & Oncology Dx Summit
      GlobeNewswire

      Genetron Health to Present at the SVB Leerink CybeRx Series: Liquid Biopsy & Oncology Dx Summit

      BEIJING, April 01, 2021 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, Nasdaq: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that management will present at the SVB Leerink CybeRx Series: Liquid Biopsy & Oncology Dx Summit on Wednesday April 7th, 2021. Interested parties may request more information by contacting their sales representative at SVB Leerink. About Genetron Holdings LimitedGenetron Holdings Limited (“Genetron Health” or the “Company”) (Nasdaq:GTH) is a leading precision oncology platform company in China that specializes in cancer molecular profiling and harnesses advanced technologies in molecular biology and data science to transform cancer treatment. The Company has developed a comprehensive oncology portfolio that covers the entire spectrum of cancer management, addressing needs and challenges from early screening, diagnosis and treatment recommendations, as well as continuous disease monitoring and care. Genetron Health also partners with global biopharmaceutical companies and offers customized services and products. For more information, please visit ir.genetronhealth.com. Safe Harbor StatementThis press release contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements about the Company’s beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties, and a number of factors could cause actual results to differ materially from those contained in any forward-looking statement. In some cases, forward-looking statements can be identified by words or phrases such as “may”, “will,” “expect,” “anticipate,” “target,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to” or other similar expressions. Further information regarding these and other risks, uncertainties or factors is included in the Company’s filings with the SEC. All information provided in this press release is as of the date of this press release, and the Company does not undertake any duty to update such information, except as required under applicable law. Investor Relations ContactUS:Hoki LukHead of Investor RelationsEmail: hluk@genetronhealth.us Phone: +1 (408) 891-9255 David Deuchler, CFAManaging Director | Gilmartin GroupEmail: ir@genetronhealth.com

    • Business Wire

      Genetron Health Presented Its Proprietary Early Screening Technology Mutation Capsule at Science/AAAS Webinar

      Genetron Holdings Limited ("Genetron Health" or the "Company", NASDAQ: GTH) sponsored a Science/AAAS Webinar, "Early cancer screening today and tomorrow: Exploring liquid biopsy profiling for diagnosis and treatment", which launched today.

    • Genetron Holdings Limited (NASDAQ:GTH) Released Earnings Last Week And Analysts Lifted Their Price Target To US$26.22
      Simply Wall St.

      Genetron Holdings Limited (NASDAQ:GTH) Released Earnings Last Week And Analysts Lifted Their Price Target To US$26.22

      Shareholders in Genetron Holdings Limited ( NASDAQ:GTH ) had a terrible week, as shares crashed 21% to US$18.25 in the...